Cabaletta Bio, Inc.
Cabaletta Bio, Inc. (CABA) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · CABA · as of Sep 30, 2025
Ownership Breakdown
80
Institutional Holders
▼ 10 vs Q2
$161.97M
Total Inst. Value
▲ $51.28M vs Q2
163.05M
Shares Outstanding
freeFloat 87.64%
69.21M
13F Shares Held
▼ 3.56M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
CABA largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC biological products, (no diagnostic substances) | 9.68M | 9.46% | 9.46% | $22.64B | Nov 14, 2025 | — held |
ADAGE CAPITAL PARTNERS GP, L.L.C. biological products, (no diagnostic substances) | 8.83M | 8.63% | 8.63% | $20.66B | Nov 14, 2025 | — held |
JENNISON ASSOCIATES LLC biological products, (no diagnostic substances) | 8.50M | 8.31% | 8.31% | $19.88B | Oct 30, 2025 | ▲ 2.48M |
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. biological products, (no diagnostic substances) | 8.36M | 8.18% | 8.18% | $19.57B | Nov 14, 2025 | ▲ 1.57M |
CORMORANT ASSET MANAGEMENT, LP biological products, (no diagnostic substances) | 5.00M | 4.89% | 4.89% | $11.70B | Nov 14, 2025 | — held |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 4.19M | 4.10% | 4.10% | $9.81B | Nov 7, 2025 | ▲ 740.0K |
MORGAN STANLEY biological products, (no diagnostic substances) | 1.47M | 2.38% | 2.38% | $3.45B | May 27, 2026 | ▲ 149.9K |
WOODLINE PARTNERS LP biological products, (no diagnostic substances) | 2.14M | 2.09% | 2.09% | $5.00B | Nov 14, 2025 | ▲ 916.9K |
HEIGHTS CAPITAL MANAGEMENT, INC biological products, (no diagnostic substances) | 2.08M | 2.04% | 2.04% | $4.88B | Nov 18, 2025 | ▼ 1.06M |
BLACKROCK, INC. biological products, (no diagnostic substances) | 1.62M | 1.58% | 1.58% | $3.79B | Nov 12, 2025 | ▲ 650.3K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
26
Increased
+11.93M shares4
New Positions
first time holders14
Decreased
−11.02M shares0
Sold Out
fully exitedNet shares change (top 50)
+913.0K
+11.93M / −11.02M
Net new holders
+16
4 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
CABA insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
14
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Das Arun Chief Business Officer | Mar 2, 2026 | Award | 175,000 | $3.30 | $577.5K | 175.0K | Form 4 ↗ |
Gerard Michael General Counsel | Mar 2, 2026 | Award | 175,000 | $3.30 | $577.5K | 175.0K | Form 4 ↗ |
Binder Gwendolyn President, Science & Tech. | Mar 2, 2026 | Award | 225,000 | $3.30 | $742.5K | 225.0K | Form 4 ↗ |
Chang David J. Chief Medical Officer | Mar 2, 2026 | Award | 225,000 | $3.30 | $742.5K | 225.0K | Form 4 ↗ |
Nichtberger Steven President & CEO | Mar 2, 2026 | Award | 674,000 | $3.30 | $2.22M | 674.0K | Form 4 ↗ |
Marda Anup Chief Financial Officer | Mar 2, 2026 | Award | 225,000 | $3.30 | $742.5K | 225.0K | Form 4 ↗ |
Chang David J. Chief Medical Officer | Jan 21, 2026 | Purchase | 8,800 | $2.26 | $19.9K | 8.8K | Form 4 ↗ |
Binder Gwendolyn President, Science & Tech. | Jan 21, 2026 | Purchase | 11,312 | $2.19 | $24.8K | 31.3K | Form 4 ↗ |
Tomasello Shawn director | Jan 21, 2026 | Purchase | 22,725 | $2.21 | $50.3K | 22.7K | Form 4 ↗ |
Gavel Steve Chief Commercial Officer | Jan 21, 2026 | Purchase | 22,170 | $2.27 | $50.2K | 22.2K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Cabaletta Bio, Inc. (CABA) is primarily owned by institutional investors, who hold approximately 42.5% of total shares outstanding. Company insiders own approximately 12.36%, while retail and public investors account for the remaining 45.19%.
The largest institutional shareholder of Cabaletta Bio, Inc. is BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC, holding approximately 9.68 million shares — equal to 9.46% of outstanding shares — as of September 30, 2025.
A total of 80 institutional investors currently hold CABA stock, with a combined institutional value of approximately $161,974,286 as of the most recent 13F filing period.
Frequently asked questions
CABA ownershipCabaletta Bio, Inc. (CABA) is primarily owned by institutional investors, who hold approximately 42.5% of shares. The largest shareholder is BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC with a 9.46% stake. Company insiders hold 12.36%. Data sourced from SEC Form 13F as of September 30, 2025.